

R&D Network Meeting

Strategic use of Drug Formulation Patents

Jens Viktor Nørgaard

Speaker / CV



Jens Viktor Nørgaard

Partner, European Patent Attorney, Teamleader
Team Biotech-Chemistry.
PhD, MSc, Royal Veterinary and Agricultural
University

jvn@hoiberg.com

HØIBERG

HØIBERG has
Medicon Valley's
largest IP group
specializing in
Life Sciences


Stockholm
Lund
Copenhagen
Malmö
Aarhus

HØIBERG
employs
55 people


HØIBERGS
clients range from
start-ups to
multi-nationals



Technologies to be patented



Loss of Exclusivity



Drug Formulation Patents

- Require technical effect:
 - PK
 - Side effects
 - Efficacy
 - Manufacturing
 - Stability
- Provide
 - Extension of effective patent term for marketed formulation
 - Composition of matter patent – not limited to particular use

**Thank you
for your
attention**



HØIBERG

European Patent Attorneys